The first patient has been dosed in a global clinical trial testing the safety and efficacy of FLT201 (avigbagene parvec), an investigational gene therapy that Spur Therapeutics is developing for Gaucher disease type 1. The Phase 3Â trial (NCT07223944) is recruiting up to 45 adults with Gaucher disease…
